(GILD) Gilead Sciences - NASDAQ
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NASDAQ (USA) | Market Cap: 156.276m USD | Total Return: 15.1% in 12m
Avg Turnover: 811M
EPS Trend: 51.3%
Qual. Beats: 0
Rev. Trend: 96.9%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Gilead Sciences, Inc. is a California-based biopharmaceutical company focused on developing and commercializing therapeutics for life-threatening diseases. Its core portfolio centers on HIV-1 infection treatments, including Biktarvy and Descovy, alongside specialized therapies for chronic hepatitis B, C, and primary biliary cholangitis. The company also maintains a significant presence in oncology through CAR T-cell therapies like Yescarta and Tecartus, and provides the antiviral Veklury for COVID-19 treatment.
The biotechnology sector relies heavily on a capital-intensive research and development model, where long-term growth is driven by the successful navigation of clinical trial phases and patent protection for novel molecular entities. Gilead extends its pipeline through a network of strategic collaborations with global pharmaceutical firms and specialized biotech entities to co-develop immunotherapies and small molecule treatments. Investors can explore more comprehensive financial metrics for GILD on ValueRay.
- Biktarvy dominance and Sunlenca adoption drive long-term HIV market share stability
- Trodelvy sales growth and oncology pipeline expansion diversify revenue beyond virology
- Declining Veklury demand creates significant year-over-year revenue headwinds for COVID-19 portfolio
- High-stakes clinical trial results for Arcus Biosciences partnership impact future valuation
- Strategic acquisitions and liver disease drug approvals offset upcoming HIV patent expirations
| Net Income: 9.22b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 0.73 > 1.0 |
| NWC/Revenue: 30.82% < 20% (prev 15.86%; Δ 14.96% < -1%) |
| CFO/TA 0.19 > 3% & CFO 10.8b > Net Income 9.22b |
| Net Debt (12.4b) to EBITDA (14.5b): 0.85 < 3 |
| Current Ratio: 1.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.25b) vs 12m ago -0.40% < -2% |
| Gross Margin: 79.35% > 18% (prev 78.29%; Δ 1.07% > 0.5%) |
| Asset Turnover: 52.76% > 50% (prev 50.92%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: 11.67 > 6 (EBIT TTM 11.7b / Interest Expense TTM 1.00b) |
| A: 0.16 (Total Current Assets 18.6b - Total Current Liabilities 9.48b) / Total Assets 56.3b |
| B: 0.25 (Retained Earnings 14.1b / Total Assets 56.3b) |
| C: 0.21 (EBIT TTM 11.7b / Avg Total Assets 56.4b) |
| D: 0.72 (Book Value of Equity 23.5b / Total Liabilities 32.8b) |
| Altman-Z'' = 4.04 = AA |
| DSRI: 1.04 (Receivables 4.74b/4.39b, Revenue 29.7b/28.7b) |
| GMI: 0.99 (GM 78.29% / 79.35%) |
| AQI: 0.94 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.03 (Revenue 29.7b / 28.7b) |
| TATA: -0.03 (NI 9.22b - CFO 10.8b) / TA 56.3b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 16, 2026, the stock is trading at USD 124.30 with a total of 6,490,627 shares traded.
Over the past week, the price has changed by -2.33%,
over one month by -3.44%,
over three months by -13.84% and
over the past year by +15.08%.
Gilead Sciences has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy GILD.
- StrongBuy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 157.8 | 27% |
P/E Trailing = 17.1252
P/E Forward = 15.2207
P/S = 5.2555
P/B = 6.6458
P/EG = 2.1441
Revenue TTM = 29.7b USD
EBIT TTM = 11.7b USD
EBITDA TTM = 14.5b USD
Long Term Debt = 20.9b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 22.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.4b USD (calculated: Debt 22.2b - CCE 9.82b)
Enterprise Value = 169b USD (156b + Debt 22.2b - CCE 9.82b)
Interest Coverage Ratio = 11.67 (Ebit TTM 11.7b / Interest Expense TTM 1.00b)
EV/FCF = 16.49x (Enterprise Value 169b / FCF TTM 10.2b)
FCF Yield = 6.07% (FCF TTM 10.2b / Enterprise Value 169b)
FCF Margin = 34.40% (FCF TTM 10.2b / Revenue TTM 29.7b)
Net Margin = 30.99% (Net Income TTM 9.22b / Revenue TTM 29.7b)
Gross Margin = 79.35% ((Revenue TTM 29.7b - Cost of Revenue TTM 6.14b) / Revenue TTM)
Gross Margin QoQ = 79.24% (prev 79.51%)
Tobins Q-Ratio = 3.00 (Enterprise Value 169b / Total Assets 56.3b)
Interest Expense / Debt = 4.53% (Interest Expense 1.00b / Debt 22.2b)
Taxrate = 14.08% (1.51b / 10.7b)
NOPAT = 10.1b (EBIT 11.7b * (1 - 14.08%))
Current Ratio = 1.97 (Total Current Assets 18.6b / Total Current Liabilities 9.48b)
Debt / Equity = 0.94 (Debt 22.2b / totalStockholderEquity, last quarter 23.5b)
Debt / EBITDA = 0.85 (Net Debt 12.4b / EBITDA 14.5b)
Debt / FCF = 1.21 (Net Debt 12.4b / FCF TTM 10.2b)
Total Stockholder Equity = 21.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.35% (Net Income 9.22b / Total Assets 56.3b)
RoE = 42.20% (Net Income TTM 9.22b / Total Stockholder Equity 21.8b)
RoCE = 27.48% (EBIT 11.7b / Capital Employed (Equity 21.8b + L.T.Debt 20.9b))
RoIC = 21.62% (NOPAT 10.1b / Invested Capital 46.6b)
WACC = 6.47% (E(156b)/V(178b) * Re(6.84%) + D(22.2b)/V(178b) * Rd(4.53%) * (1-Tc(0.14)))
Discount Rate = 6.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.33 | Cagr: -0.07%
[DCF] Terminal Value 75.94% ; FCFF base≈10.1b ; Y1≈10.4b ; Y5≈11.8b
[DCF] Fair Price = 136.8 (EV 182b - Net Debt 12.4b = Equity 170b / Shares 1.24b; r=8.35% [WACC [floored]]; 5y FCF grow 3.91% → 2.50% )
EPS Correlation: 51.29 | EPS CAGR: 16.66% | SUE: 0.48 | # QB: 0
Revenue Correlation: 96.88 | Revenue CAGR: 3.43% | SUE: 0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-6.79 | Chg30d=+1.02% | Revisions=-79% | Analysts=20
EPS next Quarter (2026-09-30): EPS=1.88 | Chg30d=-2.65% | Revisions=-26% | Analysts=19
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=-122.93% | Revisions=-85% | GrowthEPS=-109.7% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=9.59 | Chg30d=-0.94% | Revisions=-15% | GrowthEPS=+1309.3% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: -85%